FMR LLC & Abigail Johnson Maintain 12.89% Stake in Celldex (CLDX)
Ticker: CLDX · Form: SC 13G/A · Filed: Feb 9, 2024 · CIK: 744218
| Field | Detail |
|---|---|
| Company | Celldex Therapeutics, Inc. (CLDX) |
| Form Type | SC 13G/A |
| Filed Date | Feb 9, 2024 |
| Risk Level | low |
| Sentiment | bullish |
Complexity: simple
Sentiment: bullish
Topics: institutional-ownership, amendment, biotech, large-holder
TL;DR
**FMR LLC and Abigail Johnson still own 12.89% of Celldex, showing strong conviction.**
AI Summary
FMR LLC, a major investment firm, and its CEO, Abigail P. Johnson, have updated their ownership stake in Celldex Therapeutics, Inc. (CLDX) to 12.891% as of February 9, 2024. This represents a beneficial ownership of 7,050,409 shares of common stock. This matters to investors because it shows a significant, continued conviction from a large institutional investor in Celldex, potentially signaling confidence in the company's future prospects.
Why It Matters
This filing indicates that a major institutional investor, FMR LLC, and its principal, Abigail P. Johnson, continue to hold a substantial position in Celldex Therapeutics, suggesting ongoing belief in the company's value.
Risk Assessment
Risk Level: low — This filing indicates a stable, significant institutional ownership, which generally reduces volatility and provides a vote of confidence.
Analyst Insight
A smart investor would view this continued significant institutional ownership by FMR LLC as a positive signal, potentially indicating long-term confidence in Celldex Therapeutics' prospects, and might consider further research into the company's fundamentals and pipeline.
Key Numbers
- 7,050,409 — Shares Beneficially Owned (Represents the total number of Celldex Therapeutics common shares held by FMR LLC and Abigail P. Johnson.)
- 12.891% — Percent of Class (Indicates the significant ownership stake FMR LLC and Abigail P. Johnson have in Celldex Therapeutics.)
Key Players & Entities
- FMR LLC (company) — reporting person and parent holding company
- Abigail P. Johnson (person) — reporting person, likely CEO of FMR LLC
- Celldex Therapeutics, Inc. (company) — the issuer of the common stock
- 7,050,409 (dollar_amount) — total shares beneficially owned by FMR LLC and Abigail P. Johnson
- 12.891% (dollar_amount) — percentage of class owned by FMR LLC and Abigail P. Johnson
Forward-Looking Statements
- FMR LLC will maintain a significant ownership stake in Celldex Therapeutics for the foreseeable future. (FMR LLC) — high confidence, target: 12-2024
FAQ
Who are the primary reporting persons in this SC 13G/A filing?
The primary reporting persons are FMR LLC and Abigail P. Johnson, as stated in Item 1 of the filing for both entities.
What is the total number of Celldex Therapeutics, Inc. common shares beneficially owned by the reporting persons?
FMR LLC and Abigail P. Johnson beneficially own a total of 7,050,409 shares of Celldex Therapeutics, Inc. common stock, as detailed in Item 7 and Item 9 for both reporting persons.
What percentage of Celldex Therapeutics, Inc.'s common stock do the reporting persons own?
The reporting persons, FMR LLC and Abigail P. Johnson, own 12.891% of the class of Celldex Therapeutics, Inc. common stock, as indicated in Item 11 for both.
What is the CUSIP number for Celldex Therapeutics, Inc. common stock mentioned in the filing?
The CUSIP number for Celldex Therapeutics, Inc. common stock is 15117B202, as specified in the filing under 'Cusip #15117B202' and Item 2(e).
Under which rule is this Schedule 13G filed?
This Schedule 13G is filed pursuant to Rule 13d-1(b), as indicated by the checked box in the filing and further clarified in Item 3, stating FMR LLC is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G).
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on February 9, 2024 by Abigail P. Johnson regarding Celldex Therapeutics, Inc. (CLDX).